ORIC Key Statistics, Chart & Performance
The current stock price of ORIC is 8.68 USD. In the past month the price decreased by -17.49%. In the past year, price increased by 9.05%.
ORIC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.7 | 412.54B | ||
| AMGN | AMGEN INC | 15.62 | 183.97B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.89 | 122.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 18.05 | 85.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 828.43 | 55.82B | ||
| INSM | INSMED INC | N/A | 37.54B | ||
| NTRA | NATERA INC | N/A | 35.11B | ||
| BIIB | BIOGEN INC | 11.17 | 27.42B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.09 | 21.69B | ||
| INCY | INCYTE CORP | 17.22 | 21.71B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About ORIC
Company Profile
Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. The company is headquartered in South San Francisco, California and currently employs 106 full-time employees. The company went IPO on 2020-04-24. The firm is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The firm's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
Company Info
ORIC PHARMACEUTICALS INC
240 E. Grand Ave, 2nd Floor
South San Francisco CALIFORNIA 94080 US
CEO: Jacob M. Chacko
Employees: 115
Phone: 16503885600
ORIC PHARMACEUTICALS INC / ORIC FAQ
Can you describe the business of ORIC PHARMACEUTICALS INC?
Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. The company is headquartered in South San Francisco, California and currently employs 106 full-time employees. The company went IPO on 2020-04-24. The firm is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The firm's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
Can you provide the latest stock price for ORIC PHARMACEUTICALS INC?
The current stock price of ORIC is 8.68 USD. The price increased by 6.63% in the last trading session.
Does ORIC PHARMACEUTICALS INC pay dividends?
ORIC does not pay a dividend.
How is the ChartMill rating for ORIC PHARMACEUTICALS INC?
ORIC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is ORIC stock listed?
ORIC stock is listed on the Nasdaq exchange.
Would investing in ORIC PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ORIC.
ORIC Technical Analysis
ORIC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ORIC. ORIC has a great financial health rating, but its profitability evaluates not so good.
ORIC Financial Highlights
Over the last trailing twelve months ORIC reported a non-GAAP Earnings per Share(EPS) of -1.73. The EPS increased by 3.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.37% | ||
| ROE | -33.24% | ||
| Debt/Equity | 0 |
ORIC Forecast & Estimates
20 analysts have analysed ORIC and the average price target is 21.34 USD. This implies a price increase of 145.79% is expected in the next year compared to the current price of 8.68.